|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
gptkb:physician
|
|
gptkbp:approvalYear
|
2015
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
gptkb:L04AC10
|
|
gptkbp:brand
|
gptkb:Cosentyx
|
|
gptkbp:CASNumber
|
875356-43-7
|
|
gptkbp:chemicalFormula
|
C6368H9844N1692O1992S46
|
|
gptkbp:contraindication
|
active severe infections
hypersensitivity to secukinumab
|
|
gptkbp:cost
|
high
|
|
gptkbp:developedBy
|
gptkb:Novartis
|
|
gptkbp:drugClass
|
gptkb:monoclonal_antibody
|
|
gptkbp:form
|
solution for injection
prefilled syringe
vial
autoinjector
|
|
gptkbp:genericName
|
gptkb:secukinumab
|
|
gptkbp:halfLife
|
27 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cosentyx
|
|
gptkbp:indication
|
gptkb:psoriatic_arthritis
ankylosing spondylitis
plaque psoriasis
non-radiographic axial spondyloarthritis
|
|
gptkbp:KEGGID
|
D10568
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
gptkb:interleukin-17A
|
|
gptkbp:marketedIn
|
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
IL-17A inhibitor
|
|
gptkbp:MedlinePlusID
|
a615040
|
|
gptkbp:patent
|
gptkb:Novartis
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescribes
|
adults
children (for some indications)
|
|
gptkbp:prescriptionStatus
|
Rx only
|
|
gptkbp:PubChem_CID
|
DB09029
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
diarrhea
headache
upper respiratory tract infection
nasopharyngitis
oral herpes
|
|
gptkbp:storage
|
2-8°C
|
|
gptkbp:UNII
|
45Y7D6D6G4
|
|
gptkbp:website
|
https://www.cosentyx.com/
|
|
gptkbp:bfsParent
|
gptkb:Novartis
|
|
gptkbp:bfsLayer
|
4
|